We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Inseego Corp | TG:INO | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.00 | - |
From Dec 2019 to Dec 2024
By Tess Stynes
Inovio Pharmaceuticals Inc. (INO) said pharmaceutical giant Roche Holding AG (RHHBY, ROG.VX, RO.EB) will pay as much as $422.5 million in an exclusive licensing agreement for Invio's investigational gene-based vaccines for prostate cancer and hepatitis B.
Inovio's shares were up 33% at $2.96 in recent premarket trading.
The companies will collaborate on the two compounds--known as INO-5150 for prostate cancer and INO-1800 for hepatitis B--which are in preclinical development.
Under the agreement, Roche will pay $10 million upfront and as much as $412.5 million in milestone payments. Additional development milestone payments could also be made if Roche pursues using the compounds to treat other illnesses.
Inovio is entitled to receive up to double-digit tiered royalties on any product sales. Roche also obtained an option to license additional vaccine opportunities in connection with a collaborative cancer research program.
Roche's American depositary shares closed Monday at $63.39 and were inactive premarket.
Write to Tess Stynes at tess.stynes@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Inseego Chart |
1 Month Inseego Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
